The BAF complex binds to ~33% gene promoters and also to active enhancers and in the context of SMARCB1 inactivation, there results dysregulation of 1300 genes including multiple cancer-associated pathways such as CCND1/CDK4, SHH, and WNT/B-Catenin—in essence too many to contemplate therapeutic targeting [62,63,64]. Here, CDK4 is linked to cancer.